Engimmune Therapeutics
Basel
About Engimmune Therapeutics
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $16.4M
- Funding stage: Seed
- Last round: Seed (May 2022)
- Website: engimmune.com
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/engimmune-therapeutics-130232 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.